| The Pluripotential Effects of Hypolipidemic Treatment for Polycystic Ovary Syndrome (PCOS): Dyslipidemia, Cardiovascular Risk Factors and Beyond. | |
| | |
MedLine Citation:
|
PMID: 21418035 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
Polycystic ovary syndrome (PCOS) is a heterogeneous syndrome characterized by oligo- or anovulation, clinical and/or biochemical signs of hyperandrogenemia and polycystic ovaries. Clinical expression is determined by both genetic and environmental factors. Dyslipidemia is very common in lean as well as in obese women with PCOS and should be considered in the therapeutic management of the syndrome. Additionally to dyslipidemia, other risk factors for cardiovascular disease strongly associated with PCOS include insulin resistance, impaired glucose tolerance and metabolic syndrome. Therefore, the ideal therapeutic approach for PCOS would be multi targeted treatment ameliorating not only ovarian dysfunction but also cardiometabolic aspects, including dyslipidemia. Recently, a new era of hypolipidemic agents like statins has been initiated with regard to PCOS. The spectrum of statins' targets has been expanded and in vitro and in vivo studies have explored the specific effect of statins on androgen production, insulin resistance and inflammation markers in PCOS. Statins are potentially promising therapeutic agents targeting hormonal and metabolic disturbances in PCOS, though conclusive results are still pending. Since several hormonal and metabolic aberrations characterizing this multifaceted syndrome cluster and interact with each other, their effects on the lipid profile are interweaving and the therapeutic modalities targeting dyslipidemia appear to have a more broad beneficial effect. |
| | |
Authors:
|
Frangiskos Economou; Xenofon Xyrafis; Charikleia Christakou; Evanthia Diamanti-Kandarakis |
Related Documents
:
|
1463315 - Ehlers-danlos syndrome: a case report. 5015965 - Sucrose malabsorption in greenland. 19081745 - Macular and serum carotenoid concentrations in patients with malabsorption syndromes. 52635 - Suitability of the azocoupling reaction with 1-naphthyl-beta-d-glucoside for the histoc... 9557885 - Prevalence of 22q11 region deletions in patients with velopharyngeal insufficiency. 7977305 - Acute megakaryoblastic leukemia following transient myeloproliferative disorder in a pa... |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2011-3-22 |
Journal Detail:
|
Title: Current pharmaceutical design Volume: - ISSN: 1873-4286 ISO Abbreviation: - Publication Date: 2011 Mar |
Date Detail:
|
Created Date: 2011-3-22 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9602487 Medline TA: Curr Pharm Des Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
University of Athens, Medical School, 1A Zefyrou Str., Ekali 17562 Athens, Greece. e.diamanti.kandarakis@gmail.com. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Lipid-Lowering Drug Therapy in Elderly Patients.
Next Document: The Role of Vitamin D in Dyslipidemia and Cardiovascular Disease.